MiR-21 targets Fas ligand-mediated apoptosis in breast cancer cell line MCF-7

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 34, Issue 2, 2014, Pages 190-194

  Wu, Ming Fu ^a   Yang, Jie ^a   Xiang, Tao ^a   Shi, Yan Yan ^a   Liu, Li Jiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

breast tumor; FasL; miR 21; tumor immunotherapy

Indexed keywords

FAS LIGAND; MICRORNA; MIRN21 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; SIGNAL TRANSDUCTION;

APOPTOSIS; BREAST NEOPLASMS; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; SIGNAL TRANSDUCTION;

EID: 84898886304     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-014-1257-5     Document Type: Article

References (16)

1. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD 95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med, 1996,2(12):1361-1366
2. Ryan AE, Shanahan F, O'Connell J, et al. Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle, 2006,5(3):246-249
3. Müschen M, Moers C, Warskulat U, et al. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology, 2000,99(1):69-77
4. Reimer T, Herrnring C, Koczan D, et al. FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res, 2000,60(4):822-828
5. O'Connell J, Bennett MW, O'Sullivan GC, et al. The Fas counterattack: cancer as a site of immune privilege. Immunol Today, 1999,20(1):46-52
6. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 1995,270(5239):1189-1192
7. Ungefroren H, Voss M, Jansen M, et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res, 1998,58(8):1741-1749
8. Zhang W, Ding EX, Wang Q, et al. Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol, 2005, 11(23):3632-3635
9. Sayed D, He M, Hong C, et al. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem, 2011,285(26):20281-20290
10. Sayed D, Rane S, Lypowy J, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell, 2008,19(8):3272-3278
11. Chao TF, Xiong HH, Liu W, et al. MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2. J Huazhong Univ Sci Technol [Med Sci], 2013,33(4):525-552
12. Wang X, Liu Y, Chen X, et al. Impact of MiR-21 on the expression of FasL in the presence of TGF-β1. Aesthet Surg J, 2013,33(8):1186-1198
13. Wang N, Zhang CQ, He JH, et al. MiR-21 down-regulation suppresses cell growth, invasion and induces cell apoptosis by targeting FASL, TIMP3, and RECK genes in esophageal carcinoma. Dig Dis Sci, 2013,58(7):1863-1870
14. Wang P, Zhuang L, Zhang J, et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol, 2013,7(3): 334-345
15. Zhang L, Dong LY, Li YJ, et al. miR-21 represses FasL in microglia and protects against microglia-mediated neuronal cell death following hypoxia/ischemia. Glia, 2012,60(12):1888-1895
16. Buscaglia LE, Li Y. Apoptosis and the target genes of microRNA-21. Chin J Cancer, 2011,30(6):371-380